Piramal Pharma Limited

PPLPHARMAFair value region

A 6-pillar fundamental profile. Each pillar scored 0–10.

5.7/10 composite
Prism for PPLPHARMA.NS: composite 5.7 of 10, verdict Fair value regionPULSEQUALITYMOATSAFETYGROWTHVALUE0.00.00.00.00.00.0

Pulse

8.6 · Positive

Analyst revision trend (fallback)

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means stronger near-term tailwinds.

Quality

4.9 · Moderate

Piotroski 6/9, ROCE 7.0%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

3.5 · Weak

No moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

4.5 · Moderate

Int cov 2.0x

Safety looks at balance-sheet strength, leverage, and cash generation. Higher means lower financial risk.

Growth

6.2 · Moderate

Rev CAGR 11.9%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

7.3 · Moderate

MoS 15%

Value measures whether the stock is cheap relative to its intrinsic worth. Higher is cheaper.

Compare with another stock

Overlay PPLPHARMA's prism against a peer.

Share this prism

Share on XWhatsApp

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for PPLPHARMA.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.